AstraZeneca News and Activities

AstraZeneca is one of the...

• Forbes Global 2000 (#109);
• Fortune 500 Europe (#87);
• FTSE 350;
• Global Fortune 500 (#270);
• Stoxx 600;
• TOB Iconic 10,000.

AstraZeneca is a company listed under the stock ticker AZN (GB).

AstraZeneca has a direct presence in 31 countries.

AstraZeneca has 48 subsidiaries including Alexion Pharma Europe, Alexion Pharma France and Alexion Pharma Ireland.

They are in:

• Pharmaceuticals84%
• Biotechnology12%
• Other4%

Acquisition, funding and merger involving AstraZeneca.

• AstraZeneca has acquired SixPeaks Bio (posted on November 19 2025).

View the org chart displaying its 424 main executives

Most searched biographies at AstraZeneca

• Pascal Soriot, Executive Director and Chief Executive Officer
• Tony Mok, Non-Executive Director
• Philip Broadley, Chairman of the Audit Committee and Senior indepe...

Popular executive movements at AstraZeneca

• Cindy Hoots, Chief Digital Officer and Chief Information Officer, has left the company  (posted on May 27 2026).
• Maria Shipulieva Fernandez has joined the company as President, Southern Cone  (posted on May 19 2026).
• Alan Harrison, Global Head,Talent and Talent Scouting, has left the company  (posted on May 19 2026).

Click here to view some more movements at AstraZeneca

Create your alert
to follow the executive moves at AstraZeneca.

AstraZeneca has 1,914 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• The new name of Stealth BioTherapeutics is Mighty Therapeutics. (posted on June 19 2026).
• Transcend has announced the acquisition of Otsuka America Pharmaceutical  (posted on June 18 2026).
• Chiesi has announced the acquisition of Kalvista Pharmaceuticals  (posted on June 18 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Tracey Franklin - Chief People and Digital Technology Officer at Moderna
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by AstraZeneca

• Alexion data presented at the 2025 AAN Annual Meeting highlight advancements in improving care for rare neurological diseases
• AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy
• Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
• Alexion, AstraZeneca Rare Disease data at the 2024 AANEM Annual Meeting and MGFA Scientific Session further demonstrate advancement in gMG care
• Airsupra demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
• Fasenra recommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis
• Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
• Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
• Enhertu granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
• Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
• View more press releases Close

Social media about AstraZeneca

• AstraZeneca on Wikipedia, Google News & Yahoo Finance
• AstraZeneca on LinkedIn, X (Twitter) & YouTube